摘要
目的:评估中国首发缺血性卒中或短暂性脑缺血发作(TIA)的已知非瓣膜性心房颤动(NVAF)患者华法林的使用情况及使用不足的相关因素。方法:从中国国家卒中登记数据库(CNSR)中连续筛选首发缺血性卒中或TIA的NVAF患者,筛选已知心房颤动和新发心房颤动患者,评估华法林在适合抗凝治疗的已知心房颤动患者中的使用比例。采用多变量logistic回归模型评估华法林使用不足的相关因素。结果:在筛选出的11 080例首发缺血性卒中或TIA患者中,有996例(9.7%)患者存在NVAF且无抗凝治疗禁忌症,其中有592例既往已知存在心房颤动。在这些患者中,只有96例(16.2%)发病前服用了华法林,496例(83.8%)发病前未服用华法林。在服用华法林的患者中,只有1例患者入院时的国际标准化比值(INR)在治疗范围(2.0~3.0)内。依据CHADS2卒中风险评分,在卒中发生前的低危心房颤动患者中,有近20.2%的患者服用了华法林,而在中危及高危患者中,华法林的服用比例分别只有15.2%和16.4%。年老的和既往存在冠心病病史的患者服用华法林的可能性较小,而发病前服用抗血小板药物的患者更有可能服用华法林。结论:CNSR中首发缺血性卒中或TIA的NVAF患者中,适宜抗凝治疗的患者存在严重的华法林使用不足,即使接受抗凝治疗,达标率也极低。如果发病前给予合适的抗凝治疗并监测,许多由心房颤动导致的卒中和TIA就可避免。
Objective: To examine the current state of warfarin usage in nonvalvular atrial fibrillation(NVAF) patients with first-ever ischemic stroke(IS) or transient ischemic attack(TIA) in China,and to analyze the factors causing such under-usage.Methods: By accessing the China National Stroke Registry(CNSR),data on consecutive patients with known NVAF who developed first-ever IS or TIA was studied.Proportion of warfarin usage was estimated in those patients with known NVAF who should be eligible for anticoagulation therapy.Factors associated to warfarin under-usage were identified by multivariate logistic regression.Results: Of 11 080 patients with first-ever IS or TIA,996(9.7%) had NVAF and no contraindications to anticoagulation therapy and 592 of them had history of AF.Among these patients,only 96(16.2%) were on warfarin and 496(83.8%) were not.In those patients on warfarin,only 1 of his International Normalized Ratios(INRs) on admission was in the therapeutic range of 2.0~3.0.Based on the CHADS2 scores,about 20.2% low risk AF patients took warfarin,however,only 15.2% moderate and 16.4% high risk patients were on warfarin.Older patients and patients with history of coronary heart disease(CHD) were less likely to be given warfarin,while patients with history of pre-stroke antiplatelet usage were more likely to take warfarin.Conclusion: Warfarin has been significantly under-used in patients with known NVAF in China.Many strokes and TIAs caused by AF could have been prevented if warfarin was appropriately prescribed and monitored.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2012年第11期1203-1209,共7页
Chinese Journal of New Drugs
基金
国家"重大新药创制"科技重大专项(2008ZX09312-008)
卫生部卫生公益行业科研专项(200902004)
"十二五"国家科技支撑计划重大项目(2011BAI08B02)
关键词
首发卒中
心房颤动
抗凝治疗
华法林
抗栓治疗
first-ever stroke
atrial fibrillation
anticoagulation
warfarin
antithrombotic therapy